Last reviewed · How we verify
Lipopolysaccharides
Lipopolysaccharides is a Small molecule drug developed by National Jewish Health. It is currently in Phase 1 development. Also known as: Endotoxin, LPS, Clinical reference center lipopolysaccharide, LPS E. Coli O:113.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Lipopolysaccharides |
|---|---|
| Also known as | Endotoxin, LPS, Clinical reference center lipopolysaccharide, LPS E. Coli O:113 |
| Sponsor | National Jewish Health |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Immune Cell Response to Stimuli
- Endotoxin Exposure to Examine the Role of Inflammation in Alcohol Use (PHASE2)
- Investigation of the Effect of Preoperative Bowel Cleansing on Postoperative Cognitive Impairment (NA)
- Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Ulcerative Colitis and Crohn Disease (NA)
- Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Thermal Burns
- Hemoperfusion Efferon LPS During Cardiac Surgery Using Cardiopulmonary Bypass (NA)
- Efferon LPS Hemoadsorption in Patients With Acute Pancreatitis (NA)
- Clearance of Antibacterial Agents During Hemoperfusion in Patients With Sepsis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipopolysaccharides CI brief — competitive landscape report
- Lipopolysaccharides updates RSS · CI watch RSS
- National Jewish Health portfolio CI
Frequently asked questions about Lipopolysaccharides
What is Lipopolysaccharides?
Who makes Lipopolysaccharides?
Is Lipopolysaccharides also known as anything else?
What development phase is Lipopolysaccharides in?
Related
- Manufacturer: National Jewish Health — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Endotoxin, LPS, Clinical reference center lipopolysaccharide, LPS E. Coli O:113
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing